Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zonegran Postmarketing Skin/Renal AEs To Be Considered Unlabeled Events

Executive Summary

Elan should consider any postmarketing reports of allergic, skin, blood disorder and renal reactions with its new antiepileptic Zonegran to be unlabeled events, FDA told the company.
Advertisement

Related Content

Zonegran Label Revision Recommends Monitoring For Decreased Sweating
Zonegran Label Revision Recommends Monitoring For Decreased Sweating
Novartis Trileptal Has Fewer Hemopoietic, Dermatologic AEs Than Tegretol
Novartis Trileptal Has Fewer Hemopoietic, Dermatologic AEs Than Tegretol
Advertisement
UsernamePublicRestriction

Register

PS035834

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel